OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

TAIPEI, TW, Jan 12, 2026 - (ACN Newswire via SeaPRwire.com) - OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC.Under the terms of the agreement,…

Charlie’s Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape ProductsIKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products.The IKE Licensing Agreement provides CHUC with a first mover…